ravulizumab
Selected indexed studies
- Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (Ann Neurol, 2023) [PMID:36866852]
- Ravulizumab. (, 2012) [PMID:31643795]
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. (Blood, 2019) [PMID:30510080]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2023) pubmed
- Ravulizumab. (2012) pubmed
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. (2019) pubmed
- Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. (2025) pubmed
- Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. (2023) pubmed
- Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. (2022) pubmed
- Ravulizumab: A Review in Generalised Myasthenia Gravis. (2023) pubmed
- Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder. (2024) pubmed
- Ravulizumab: First Global Approval. (2019) pubmed
- Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders. (2025) pubmed